All Stories

  1. Storage-induced spectral changes of human platelet-rich plasma revealed by SERS

    Article • Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy, February 2026, Elsevier

    Professor Vladimir V Rafalskiy

  2. Pharmacoepidemiological analysis of drug therapy for asthenic syndrome as provided in Kaliningrad region

    Article • Research Results in Pharmacology, September 2025, Belgorod National Research University

    Professor Vladimir V Rafalskiy

  3. Analysis of pharmacotherapy practice in patients after myocardial infarction: results of a prospective open study «PROMETHEUS»

    Article • Siberian Journal of Clinical and Experimental Medicine, July 2025, Cardiology Research Institute

    Professor Vladimir V Rafalskiy

  4. Analysis of methotrexate use practice in patients with rheumatoid and psoriatic arthritis

    Article • FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology, May 2025, IRBIS

    Professor Vladimir V Rafalskiy

  5. Sers-based methodology for nanomolar methotrexate concentration detection for clinics

    Article • Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy, April 2025, Elsevier

    Professor Vladimir V Rafalskiy

  6. Tirzepatide for Obesity Treatment and Diabetes Prevention

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2025, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  7. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

    Article • The Lancet, January 2025, Elsevier

    Professor Vladimir V Rafalskiy

  8. Real-world data for monitoring antimicrobial resistance to urinary tract infection pathogens

    Article • Real-World Data & Evidence, December 2024, Publishing House OKI

    Professor Vladimir V Rafalskiy

  9. Spectral biomarkers of antiplatelet therapy effectiveness revealed by SERS

    Article • November 2024, SPIE

    Professor Vladimir V Rafalskiy

  10. Cardiovascular events in patients with psoriasis and psoriatic arthritis treated with JAK/TYK inhibitors: A systematic review and meta‐analysis

    Article • Journal of the European Academy of Dermatology and Venereology, November 2024, Wiley

    Professor Vladimir V Rafalskiy

  11. Toxic Reactions in Probable and Confirmed Methotrexate Overdose in Rheumatology Patients: A Case Series

    Article • Safety and Risk of Pharmacotherapy, November 2024, SCEEMP

    Professor Vladimir V Rafalskiy

  12. Application of Raman spectroscopy using an original optical sensor to assess the laboratory efficacy of antiplatelet drugs

    Article • Medical alphabet, November 2024, Alfmed LLC

    Professor Vladimir V Rafalskiy

  13. Risankizumab for Ulcerative Colitis

    Article • JAMA, September 2024, American Medical Association (AMA)

    Professor Vladimir V Rafalskiy

  14. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, July 2024, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  15. Dataset of human platelets SERS spectra from individuals with acute coronary syndrome

    Article • Data in Brief, June 2024, Elsevier

    Professor Vladimir V Rafalskiy

  16. Enhancing the Efficacy and Safety of Methotrexate Treatment: A Focus on Drug Interactions (Review)

    Article • Safety and Risk of Pharmacotherapy, April 2024, SCEEMP

    Professor Vladimir V Rafalskiy

  17. Search for predictors of complications of acute coronary syndrome with ST segment elevation – protocol of a prospective open cohort study PROMETHEUS

    Article • Siberian Journal of Clinical and Experimental Medicine, April 2024, Cardiology Research Institute

    Professor Vladimir V Rafalskiy

  18. Modern doctors' view on the problem of diagnostics and treatment of asthenic syndrome in different regions of the Russian Federation

    Article • Research Results in Pharmacology, January 2024, Belgorod National Research University

    Professor Vladimir V Rafalskiy

  19. Analysis of the characteristics of pharmacotherapy for outpatients with cardiovascular diseases in the Russian Federation based on the results of an online survey of doctors

    Article • Lechaschi Vrach, December 2023, Open Systems Publications

    Professor Vladimir V Rafalskiy

  20. Surface-enhanced Raman spectroscopy for searching pharmacodynamic predictors of response to antiplatelet therapy

    Article • Siberian Journal of Clinical and Experimental Medicine, August 2023, Cardiology Research Institute

    Professor Vladimir V Rafalskiy

  21. Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials

    Article • International Journal of Obesity, July 2023, Springer Science + Business Media

    Professor Vladimir V Rafalskiy

  22. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, June 2023, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  23. 1704-P: Efficacy and Safety of Tirzepatide for Weight Loss—A Meta-analysis of Randomized Controlled Trials

    Article • Diabetes, June 2023, American Diabetes Association

    Professor Vladimir V Rafalskiy

  24. Assessment of Safety and Prophylactic Efficacy of the EpiVacCorona Peptide Vaccine for COVID-19 Prevention (Phase III)

    Article • Vaccines, May 2023, MDPI AG

    Professor Vladimir V Rafalskiy

  25. Dynamics of endothelial function indexes in patients with post-Covid syndrome using a combination drug of ethylmethylhydroxyperidine succinate/vitamin B6

    Article • Research Results in Pharmacology, May 2023, Belgorod National Research University

    Professor Vladimir V Rafalskiy

  26. JAK-inhibitors: clinical pharmacology and application perspectives

    Article • Reviews on Clinical Pharmacology and Drug Therapy, March 2023, ECO-Vector LLC

    Professor Vladimir V Rafalskiy

  27. Specifics of motivation of volunteers participating in in a clinical trial of the COVID-19 vaccine

    Article • Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice, March 2023, Publishing House OKI

    Professor Vladimir V Rafalskiy

  28. Study on Tirzepatide's Effectiveness in Treating Obesity

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, July 2022, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  29. Spectral homogeneity of human platelets investigated by SERS

    Article • PLOS One, May 2022, PLOS

    Professor Vladimir V Rafalskiy

  30. The results of phase III multicenter open randomized controlled study REM-Chol-III-16 in patients with intrahepatic cholestasis syndrome caused by chronic diffuse liver diseases

    Article • Terapevticheskii arkhiv, December 2021, LLC Obyedinennaya Redaktsiya

    Professor Vladimir V Rafalskiy

  31. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2021, New England Journal of Medicine (NEJM/MMS)

    Dr Nazarii Kobyliak, Professor Vladimir V Rafalskiy

  32. Spectral and time-resolved photoluminescence of human platelets doped with platinum nanoparticles

    Article • PLOS One, September 2021, PLOS

    Professor Vladimir V Rafalskiy

  33. NMR spectroscopy reveals acetylsalicylic acid metabolites in the human urine for drug compliance monitoring

    Article • PLOS One, March 2021, PLOS

    Professor Vladimir V Rafalskiy

  34. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, January 2021, New England Journal of Medicine (NEJM/MMS)

    Professor John GF Cleland, Professor Vladimir V Rafalskiy

  35. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, January 2021, New England Journal of Medicine (NEJM/MMS)

    Professor Deepak L Bhatt, Professor Vladimir V Rafalskiy

  36. The use of antiviral drug based on technologically processed antibodies to interferon-γ, CD4 receptor and histamine in the treatment of influenza in adults: results of a multicenter open-label randomized comparative trial with oseltamivir

    Article • Infekcionnye bolezni, January 2021, Dynasty Publishing House

    Professor Vladimir V Rafalskiy

  37. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials

    Article • European Journal of Heart Failure, October 2020, Wiley

    Professor John GF Cleland, Professor Vladimir V Rafalskiy

  38. Surface-enhanced Raman spectroscopy for antiplatelet therapy effectiveness assessment

    Article • Laser Physics Letters, March 2020, Institute of Physics Publishing

    Professor Vladimir V Rafalskiy

  39. Prospects for Raman spectroscopy in cardiology

    Article • CARDIOVASCULAR THERAPY AND PREVENTION, March 2020, Silicea - Poligraf, LLC

    Professor Vladimir V Rafalskiy

  40. Dataset of human platelets in healthy and individuals with cardiovascular pathology obtained by Surface-enhanced Raman spectroscopy

    Article • Data in Brief, January 2020, Elsevier

    Professor Vladimir V Rafalskiy

  41. Treatment of acute respiratory viral infections: results of a multicenter, double-blind, placebo-controlled, randomized clinical trial

    Article • Infekcionnye bolezni, January 2020, Dynasty Publishing House

    Professor Vladimir V Rafalskiy

  42. Single human platelet study using surface-enhanced Raman spectroscopy as a perspective tool for antiplatelet therapy effectiveness prediction

    Article • November 2019, SPIE

    Professor Vladimir V Rafalskiy

  43. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, October 2019, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, Professor John GF Cleland

  44. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2019, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  45. Distribution and antibiotic resistance profile of key gram-negative bacteria that cause community-onset urinary tract infections in the Russian Federation: RESOURCE multicentre surveillance 2017 study

    Article • Journal of Global Antimicrobial Resistance, September 2019, Elsevier

    Professor Vladimir V Rafalskiy

  46. Income Inequality and Outcomes in Heart Failure

    Article • JACC Heart Failure, April 2019, Elsevier

    Dr Joao Pedro Ferreira, Professor Vladimir V Rafalskiy

  47. Antibiotic resistance of pathogens causing uncomplicated urinary tract infections in Russian Federation

    Article • Urology Herald, October 2018, Rostov State Medical University

    Professor Vladimir V Rafalskiy

  48. Growth differentiation factor‐15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM‐HF trial

    Article • European Journal of Heart Failure, September 2018, Wiley

    Professor Vladimir V Rafalskiy

  49. EPIDEMIOLOGY OF UNCOMPLICATED OUTPATIENT URINARY TRACT INFECTIONS IN THE RUSSIAN FEDERATION

    Article • Urology Herald, July 2018, Rostov State Medical University

    Professor Vladimir V Rafalskiy

  50. Cost-of-Illness Analysis of Type 2 Diabetes Mellitus in the Russian Federation: Results from Russian multicenter observational pharmacoepidemiologic study of diabetes care for patients with type 2 diabetes mellitus (FORSIGHT-Т2DM)

    Article • Diabetes Mellitus, February 2018, Endocrinology Research Centre

    Professor Vladimir V Rafalskiy

  51. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM‐HF

    Article • European Journal of Heart Failure, November 2017, Wiley

    Professor Vladimir V Rafalskiy

  52. Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction

    Article • Journal of the American College of Cardiology, November 2017, Elsevier

    Professor Vladimir V Rafalskiy

  53. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation

    Article • Circulation Heart Failure, October 2017, Wolters Kluwer Health

    Professor Vladimir V Rafalskiy

  54. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, June 2017, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, luigi gnudi

  55. The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF

    Article • American Heart Journal, June 2017, Elsevier

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  56. Assessing routine healthcare pattern for type 2 diabetes mellitus in Russia: the results of рharmacoepidemiological study (FORSIGHT-DM2)

    Article • Diabetes Mellitus, March 2017, Endocrinology Research Centre

    Professor Vladimir V Rafalskiy

  57. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial

    Article • Diabetes Obesity and Metabolism, January 2017, Wiley

    Professor Vladimir V Rafalskiy

  58. LOW DOSAGE ACETYLSALICYLIC ACID: A VARIETY OF FORMULATIONS

    Article • CARDIOVASCULAR THERAPY AND PREVENTION, January 2017, Silicea - Poligraf, LLC

    Professor Vladimir V Rafalskiy

  59. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction

    Article • European Journal of Heart Failure, November 2016, Wiley

    Professor Vladimir V Rafalskiy, Professor john j mcmurray

  60. Efficacy and safety of Ergoferon versus oseltamivir in adult outpatients with seasonal influenza virus infection: a multicenter, open-label, randomized trial

    Article • International Journal of Infectious Diseases, September 2016, Elsevier

    Professor Vladimir V Rafalskiy

  61. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background TherapyCLINICAL PERSPECTIVE

    Article • Circulation Heart Failure, September 2016, Wolters Kluwer Health

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  62. Sharing Data from Cardiovascular Clinical Trials — A Proposal

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2016, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, Professor Deepak L Bhatt

  63. Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization

    Article • Journal of the American College of Cardiology, July 2016, Elsevier

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  64. Importance of Clinical Worsening of Heart Failure Treated in the Outpatient SettingCLINICAL PERSPECTIVE

    Article • Circulation, April 2016, Wolters Kluwer Health

    Professor Vladimir V Rafalskiy, Professor john j mcmurray

  65. Influenza Vaccination in Patients With Chronic Heart Failure

    Article • JACC Heart Failure, February 2016, Elsevier

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  66. Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection FractionCLINICAL PERSPECTIVE

    Article • Circulation Heart Failure, January 2016, Wolters Kluwer Health

    Professor Vladimir V Rafalskiy, Professor john j mcmurray

  67. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes

    Article • Diabetes Obesity and Metabolism, December 2015, Wiley

    Professor Vladimir V Rafalskiy, luigi gnudi

  68. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2015, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, Professor john j mcmurray, Prof. Francisco Marin , Ponnusamy Saravanan

  69. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2015, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, Ponnusamy Saravanan

  70. Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2015, New England Journal of Medicine (NEJM/MMS)

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  71. Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores

    Article • Journal of the American College of Cardiology, November 2015, Elsevier

    Professor Vladimir V Rafalskiy, Professor john j mcmurray

  72. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF

    Article • European Heart Journal, July 2015, European Society of Cardiology

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  73. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

    Article • American Heart Journal, May 2015, Elsevier

    Professor Vladimir V Rafalskiy, Professor john j mcmurray, Professor Tzung-Dau Wang, Professor Rayaz Ahmed Malik, Prof. Francisco Marin , Ponnusamy Saravanan

  74. Pharmacokinetic peculiarities of intravenous and oral ciprofloxacin administration in preoperative prophylaxis in patients with benign prostatic hyperplasia

    Article • Reviews on Clinical Pharmacology and Drug Therapy, December 2014, ECO-Vector LLC

    Professor Vladimir V Rafalskiy

  75. Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes

    Article • Diabetes Care, December 2014, American Diabetes Association

    Professor Vladimir V Rafalskiy

  76. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

    Article • European Heart Journal, November 2014, European Society of Cardiology

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  77. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

    Article • Circulation, November 2014, Wolters Kluwer Health

    Professor Vladimir V Rafalskiy, Professor john j mcmurray, Professor Thomas Munzel or Muenzel, Dr William D Strain

  78. P9: Efficacy and safety of simeprevir in treatment naïve HCV genotype 1‐infected patients with METAVIR F2 fibrosis: QUEST‐1 and QUEST‐2 Phase III studies

    Article • Journal of Viral Hepatitis, October 2014, Wiley

    Professor Vladimir V Rafalskiy

  79. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2014, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy, Professor john j mcmurray, Professor Thomas Munzel or Muenzel, Dr William D Strain

  80. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

    Article • The Lancet, August 2014, Elsevier

    Professor Vladimir V Rafalskiy

  81. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)

    Article • European Journal of Heart Failure, June 2014, Wiley

    Professor john j mcmurray, Professor Vladimir V Rafalskiy

  82. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: The randomized PILLAR study

    Article • Hepatology, October 2013, Wiley

    Professor Vladimir V Rafalskiy

  83. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact

    Article • European Journal of Heart Failure, September 2013, Wiley

    Professor Vladimir V Rafalskiy, Professor john j mcmurray, Dr William D Strain

  84. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge in Russian practice

    Article • European Heart Journal, August 2013, European Society of Cardiology

    Professor Vladimir V Rafalskiy

  85. Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial

    Article • Gastroenterology, May 2013, Elsevier

    Professor Vladimir V Rafalskiy

  86. 1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL

    Article • Journal of Hepatology, April 2013, Elsevier

    Professor Vladimir V Rafalskiy

  87. Ferric Carboxymaltose Prevents Recurrence of Anemia in Patients With Inflammatory Bowel Disease

    Article • Clinical Gastroenterology and Hepatology, March 2013, Elsevier

    Professor Vladimir V Rafalskiy

  88. Eltrombopag before Procedures in Patients with Cirrhosis and Thrombocytopenia

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2012, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  89. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

    Article • Hepatology, August 2010, Wiley

    Professor Vladimir V Rafalskiy

  90. 247 PREDICTING TREATMENT OUTCOME AMONG SLOW RESPONDERS: A RETROSPECTIVE ANALYSIS OF THE SUCCESS STUDY

    Article • Journal of Hepatology, April 2010, Elsevier

    Professor Vladimir V Rafalskiy

  91. P300 Does in vitro antimicrobial resistance predict clinical outcomes in urinary tract infections: systematic review and metaanalysis

    Article • International Journal of Antimicrobial Agents, July 2009, Elsevier

    Professor Vladimir V Rafalskiy

  92. PREVALENCE AND RISK FACTORS OF UNCOMPLICATED UTI: MULTICENTRE STUDY SONAR

    Article • European Urology Supplements, March 2008, Elsevier

    Professor Vladimir V Rafalskiy

  93. 3-5 DAYS FLUOROQUINOLONES THERAPY IS MORE EFFECTIVE FOR ACUTE UNCOMPLICATED CYSTITIS THEN SINGLE DOSE FOSFOMYCIN: SYSTEMATIC REVIEW AND META-ANALYSIS

    Article • European Urology Supplements, March 2008, Elsevier

    Professor Vladimir V Rafalskiy

  94. Antimicrobial susceptibility of pathogens isolated from adult patients with uncomplicated community-acquired urinary tract infections in the Russian Federation: two multicentre studies, UTIAP-1 and UTIAP-2

    Article • International Journal of Antimicrobial Agents, August 2006, Elsevier

    Professor Vladimir V Rafalskiy

  95. Quinolones for uncomplicated acute cystitis in women

    Article • Cochrane Database of Systematic Reviews, July 2006, Wiley

    Professor Vladimir V Rafalskiy

  96. Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2006, New England Journal of Medicine (NEJM/MMS)

    Professor Daniel D Shouval, Professor Vladimir V Rafalskiy

  97. A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2006, New England Journal of Medicine (NEJM/MMS)

    Professor Vladimir V Rafalskiy

  98. Quinolones for uncomplicated acute cystitis in women

    Article • April 2002, Wiley

    Professor Vladimir V Rafalskiy